Neurocrine Biosciences | NBIX - Gross Profit On Sales

Stock Price
141.25
Daily Change
3.32 2.41%
Monthly
0.45%
Yearly
15.19%
Q1 Forecast
131.87

Neurocrine Biosciences reported $780.9M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Acadia Pharmaceuticals USD 256.99M 13.15M Sep/2025
Agios Pharmaceuticals USD 11.2M 448K Sep/2025
ALKERMES USD 265.83M 8.06M Sep/2025
Alnylam Pharmaceuticals USD 1.05B 418.14M Sep/2025
Amgen USD 6.48B 307M Sep/2025
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 631.2M 39.27M Sep/2025
Cytokinetics USD 1.94M 64.83M Sep/2025
Dynavax Technologies USD 78.57M 24.17M Jun/2025
Exelixis USD 579.18M 30.39M Sep/2025
Gilead Sciences USD 5.58B 453M Jun/2025
Halozyme Therapeutics USD 281.77M 2.41M Sep/2025
Incyte USD 1.27B 130.22M Sep/2025
Ionis Pharmaceuticals USD 155M 293M Sep/2025
Neurocrine Biosciences USD 780.9M 104.7M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
Prothena USD 2.42M 38.52M Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Repligen USD 100.52M 9.37M Sep/2025
Sarepta Therapeutics USD 247.9M 209.96M Sep/2025
Teva Pharmaceutical Industries USD 2.66B 351M Dec/2025
Ultragenyx Pharmaceutical USD 131.94M 11.55M Sep/2025
Vertex Pharmaceuticals USD 2.66B 104.4M Sep/2025